Screening tools and programmes for intimate partner violence in antenatal and postpartum healthcare across Europe: a scoping review with quality assessment Authors: Anne Katrine Normann, Maria Noemi Paradiso, Anne-Line Brülle, Simone Garzon, Karen Andreasen, Valeria Donisi, Lidia Del Piccolo, Paola Manfredi, Jan Stener Jørgensen, Ditte S Linde Published: 2026 ABSTRACT AbstractBackgroundIntimate partner violence (IPV) during pregnancy causes serious harm to both the mother and the child. The magnitude of the problem is likely underestimated due to the sensitive nature of the topic and lack of consensus on screening practices, including frequency, tools, and whether screening should be systematic or risk-based. This scoping review aimed to map existing screening tools and healthcare-based screening programmes for detecting IPV in European countries within antenatal and postpartum care.MethodsJoanna Briggs Institute methodology was used and reported following PRISMA-ScR guidelines. Seven databases (Embase, PsycINFO, SocINDEX, PubMed, Web of Science, Scopus, and CINAHL) were searched up to June 2025 to identify screening tools used in European countries. A quality assessment was conducted. To identify current screening programmes within antenatal and postpartum healthcare systems, representatives from 46 European countries were consulted.ResultsTwenty-four studies were included, and methodological quality ranged from low to serious risk of bias. Thirteen screening tools for physical, emotional, and sexual IPV were identified. No tools for stalking or digital violence were found. Most studies were cross-sectional. Data were received from 22 of 46 European countries (48%) regarding screening programmes in antenatal or post-partum care: 17 countries have screening programmes, while five reported none. The Abuse Assessment Screen (AAS) and the Woman Abuse Screening Tool (WAST) were the tools most commonly used in both the literature and screening programmes. Most countries with screening program recommendations, recommended a universal screening approach.ConclusionScreening tools and practices for detecting IPV during antenatal and post-partum care vary substantially across Europe, highlighting a lack of evidence and consensus on screening tools for IPV within antenatal and postpartum care.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12884-026-09473-8.Keywords: Intimate Partner Violence, Screening tools, Screening Programmes, Antenatal Care, Postpartum Care, Maternal Health Background Intimate partner violence (IPV) refers to behaviour within an intimate relationship that causes physical, sexual, or emotional harm to those involved. This definition encompasses violence perpetrated by both current and former partners and coercive acts that occur across diverse relationship types and settings [1]. IPV is a persistent and complex public health issue that inflicts human, social, and economic harm. The World Health Organization (WHO) estimates that the lifetime prevalence of IPV among ever-married or partnered women aged 15–49 years is 27% globally [2]. Data from Europe vary extensively, with rates ranging from 4 to 52% [3, 4]. Yet, the magnitude of the issue is likely underestimated due to underreporting, differences in how countries monitor and register IPV, lack of population-based survey data on IPV [2], and differences in socio-cultural acceptance of the issue [5]. Globally, the prevalence of IPV during pregnancy is estimated at 6–25% [5, 6]. In Europe, reported prevalence ranges from 5 to 63% [5–7]. Violence against women in the antenatal and postpartum period is associated with severe maternal and infant health consequences. IPV has been linked to maternal physical injury, mental health disorders, adverse reproductive outcomes, and poor infant health, including preterm birth, low Apgar scores, and low birth weight [8]. Antenatal and postpartum healthcare contacts offer a critical window of opportunity to identify women experiencing IPV [9]. Women may feel more comfortable disclosing violence due to the frequent and regular interaction with healthcare providers, as antenatal care is perceived as a safe and legitimate setting for discussing sensitive issues and concerns for the unborn child, which may further motivate disclosure [10]. Nevertheless, screening for IPV during antenatal and postpartum care remains widely debated. International guidelines, including those from the WHO highlight both the potential benefits and limitations of different screening approaches [11]. Universal screening assesses all women in healthcare settings, while risk-based screening relies on clinical indicators. Although both approaches increase IPV identification, consistent reductions in IPV or improvements in health outcomes have not been demonstrated. Accordingly, no global consensus exists on recommending risk-based or universal IPV screening in antenatal and post-partum care. Concerns about universal screening relate to limited evidence of benefit and potential screening-related risks such as the substansial strain it places on already overburdened healthcare systems, particularly in high-prevalence, resource-constrained settings with limited referral capacity [11]. Proponents argue that antenatal care offers a unique screening opportunity, given women’s frequent healthcare contact and heightened vulnerability to IPV during pregnancy. Furthermore, universal screening has been shown to increase the identification of women experiencing violence [5, 12]. Research on systematic IPV screening in healthcare has expanded in recent years, with new evidence and programmes emerging to inform future guidelines during pregnancy and early parenthood. However, evidence across European countries remains heterogeneous, and it is unclear which programmes are implemented and which screening approaches and tools are used or are most effective [13]. This scoping review aims to map IPV screening tools and healthcare-based screening programmes during pregnancy and the postpartum period across Europe. Materials and methods This scoping review methodology was guided by Arksey and O’Mally and further refined by the Joanna Briggs Institute framework, comprising five stages: (1) identification of research question, (2) identification of relevant studies, (3) study selection, (4) data extraction and (5) collation, summary and reporting [14]. The review was reported in accordance with the Preferred Reporting Item for Systematic Review and Meta Analysis extension for Scoping Reviews statement for scoping reviews [15]. Protocol and registration The study protocol was prospectively registered at the Open Science Framework (OSF): DOI: https://doi.org/10.17605/OSF.IO/TQJWG. Identification of scientific literature Eligibility criteria and inclusion The inclusion criteria were defined according to the PEOS framework: Population, exposure, outcome, setting. Studies with participants who were expecting a baby (+ 15 years), new parents (within one-year post-partum) and who experienced IPV were considered for inclusion. Studies with healthcare providers were excluded. Studies were included if outcomes reported screening of physical, emotional and sexual IPV and conflicts in the antenatal and postpartum healthcare setting. We excluded articles about screening tools for perpetrators. Studies conducted in clinical settings related to pregnancy and the postpartum period were eligible for inclusion. Only studies conducted in European countries (n = 46), in English-language and published within the last 15 years were included. To identify screening tools, a systematic block search strategy for scientific databases was developed by author MNP in collaboration with an experienced librarian at The University of Southern Denmark and systematically applied to the following databases: Embase, PsycINFO, SocINDEX, PubMed, Web of Science, SCOPUS, and CINAHL. Various search terms were used, including “screen* OR identification OR identifying OR identify OR identified OR detect* OR disclos*” AND “intimate OR spouse* OR domestic OR physical OR sex* OR abusive OR controlling OR violent OR interpersonal OR digital OR economic OR material OR psychological OR emotional”. Detailed search strings are presented in the supplementary material (Additional file 1). The databases were searched until 22 June 2025. Study selection All retrieved references were imported into Covidence [16], where duplicates were identified and removed. Titles and abstracts were independently screened by two authors (AKN, MNP), and full texts of potentially relevant articles were subsequently assessed independently by the same authors. Discrepancies were resolved through discussion, and if consensus could not be reached, a third author (DSL or KA) made the final decision. Data extraction of scientific literature Two authors (AKN, MNP) extracted data into Covidence. The extracted variables included: Author, year, journal, country, study design, participants/population, type and main characteristics of the screening tool or program, type of violence detected, number of screening questions, clinical context, language, timing of screening, screening approach (digital or face-to-face), sensitivity and specificity of screening tools, feasibility, and socio-demographic characteristics of the study population (e.g., age, gender, socio-economic status, sexual orientation). A detailed overview of sociodemographic variables is available (Additional file 2). Quality assessment of scientific literature Due to the different design of the studies, several quality assessment tools were employed: The Appraisal tool for Cross-Sectional Studies (AXIS) [17] was applied for cross-sectional studies [7, 9, 18–27] and for mixed-method studies [28–31] the Mixed-Methods Appraisal Tool (MMAT) [32] was used. For cohort studies, depending on whether they investigated exposure [33, 34] or intervention [35], the Risk of Bias in Non-Randomised Studies of Exposure (ROBINS-E) [36] or the Risk of Bias in Non-Randomised Studies-of Intervention (ROBINS-I) were used [37]. Finally, the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) [38] and the Revised Tool for Assessing Risk of Bias in Randomized Trials (RoB2) [39] were applied respectively for diagnostic test accuracy studies [40] and for randomised controlled trials studies [41]. Assessment was independently carried out by two evaluators (AKN and MNP). Evaluations were discussed until unanimous consent was reached. Healthcare-based screening programmes To identify existing healthcare-based screening programs within antenatal and postpartum healthcare across Europe, all 46 member states of the Council of Europe were contacted. At first level, National Health Authorities or major National Professional bodies were reached by e-mail using a standardized inquiry or contacted through online contact forms. If these actors did not respond – or if they referred us to alternative contacts at a lower administrative or operational level – authors subsequently contacted these organisations, e.g., regional institutions, professional organisations, NGOs, women’s shelters and organisations supporting individuals affected by violence. To supplement these data, researchers identified through publications and professional networks were contacted directly, with no further attempts after three contacts. Data were collected from July to December 2025. Data extraction of healthcare-based screening programmes Concerning the data collection process, we maintained a structured Excel sheet in which countries were color-coded according to their response status. Information from each country was systematically recorded, and all unrestricted materials were included, such as national recommendations, maternity care guidelines, legal texts, and documents in other languages. Results Characteristics of included sources Scientific studies The scientific database search yielded 3,257 records after which 594 duplicates were removed, and 2,663 records underwent title and abstract screening. A total of 43 articles underwent full text screening, and 22 studies were included. An additional two articles were identified through reference checking, and in total, 24 scientific articles were included in the review. Figure 1 shows the PRISMA flow diagram of the study selection process (Fig. 1). . Of the 24 included studies, the majority were conducted in Sweden (n = 5) [18–20, 22, 28, 33], Spain (n = 4) [21, 26, 40, 42], and Norway (n = 3) [23, 34, 41]. Three studies were conducted in Denmark and Spain [9, 35, 43], two were conducted in Greece [27, 44], and one in Cyprus [29], England [30], Germany [31], Iceland [25], and Turkey [24]. Finally, only one [7] study involved multiple countries (Belgium, Iceland, Denmark, Estonia, Norway, and Sweden). Considerable methodological heterogeneity was observed across the included studies. Of the 24 articles, 13 employed a cross-sectional design, four studies used mixed-methods approaches, and four were cohort studies. In addition, one study was a randomised controlled trial (RCT) [41], and one was a diagnostic test accuracy (DTA) study [40]. Differences in the clinical setting were also found i.e., child healthcare centers, antenatal care and midwifery clinics. Across all included studies, the target population predominantly consisted of pregnant women aged 25–34 years with a college or university education. Two studies included populations with lower levels of education [24, 29]. In one study the majority of women lived in arranged marriages [24]. No studies focused specifically on ethnic minorities; however, some studies had subgroups of ethnic minorities (Table 1). Table 1Overview of the included studiesAuthor (year)Country(ies)Study designSample sizeTarget populationClinical contextAlmqvist [28]SwedenMixed methodsn = 198Mothers/parentsChild healthcare centreAndreasen [35]Denmark and SpainCohortn = 16.068Pregnant womenAntenatal careAndreasen [43]Denmark and SpainCohortn = 19.442Pregnant womenAntenatal careEngström [18]SwedenCross-sectionaln = 67ParentsChild healthcare centreEikemo [20]SwedenCross-sectionaln = 3399Pregnant womenMidwifery clinicsEikemo [19]SwedenCross-sectionaln = 3399Pregnant womenMidwifery clinicsEscribà-Agüir [21]SpainCross-sectionaln = 1329Pregnant womenPrimary care centreFernández-López [9]Denmark and SpainCross-sectionaln = 17.220 (DK); n = 2.222 (ES)Pregnant womenAntenatal careFinnbogadóttir [33]SwedenCohortn = 1939Pregnant womenAntenatal careFinnbogadóttir [22]SwedenCross-sectionaln = 1939Pregnant womenAntenatal careFlaathen [41]NorwayRCTn = 317Pregnant women + mothersMaternal and child health centreFlaathen [21]NorwayCross-sectionaln = 1788Pregnant womenMaternal and child health centreHadjigeorgiou [29]CyprusMixed methodsn = 301Pregnant womenPerinatal care departmentsLukasse [7]Belgium, Iceland, Denmark, Estonia, Norway and SwedenCross-sectionaln = 7174Pregnant womenAntenatal careMartin-de-las-Heras [42]SpainCohortn = 779Pregnant womenObstetric departments at public hospitalsMcConnell [30]EnglandMixed methodsn = 21ParentsChild protection/social work settingÖzkan-Şat [24]TurkeyCross-sectionaln = 358Pregnant womenPublic hospitalsStöckl [31]GermanyMixed methodn = 401MothersMaternity wardSvavarsdottir [25]IcelandCross-sectionaln = 208Women (pregnant and non-pregnant)Emergency departments and high-risk prenatal care clinicsSørbø [34]NorwayCohortn = 53.065Pregnant womenRoutine antenatal careVelasco [26]SpainCross-sectionaln = 779Pregnant women (second and third trimester)Obstetric departments at public hospitalsVivilaki [27]GreeceCross-sectionaln = 91MothersPostnatal unitsVivilaki [44]GreeceCross-sectionaln = 579MothersMaternity departmentsZapata-Calvente [40]SpainDiagnostic test accuracyn = 592Pregnant womenAntenatal care Overview of the included studies Mothers/ parents Healthcare-based screening programmes Twenty-four countries did not reply to our request for data whilst data was received from 22 countries (48%); five countries responded that they did not have a specific health-care based screening programme or national guideline (Armenia, Germany, Poland, Romania, Turkey), whilst 17 had various programs (Belgium, Denmark, Finland, France, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Slovenia, Spain, Sweden, Switzerland). The institutional level of the responding bodies varied between countries; documents were obtained from ministries of health (n = 8, 36%), governmental health agencies (n = 8, 36%), or nationally coordinated health programmes (n = 6, 27%). Detailed findings from the European mapping are presented (Additional file 3). Screening tools and approaches Scientific studies Most of the included studies assessed multiple forms of IPV. Specifically, physical, emotional, and sexual violence were identified in most of the studies included (n = 19; 79%). Tools for identifying controlling behaviour were limited (n = 1; 4%) and no screening tools identifying cyber/digital violence, economic violence, and stalking were found. Overall, thirteen different screening tools for IPV detection were identified. The most frequently used instruments were the Abuse Assessment Screen (AAS) [45] and the Women Abuse Screening Tool (WAST) [46] either alone or in combination. The various screening tools were available in 13 different languages specifically, Danish, English, Estonian, Flemish, German, Greek, Icelandic, Norwegian, Spanish, Somali, Swedish, Turkish and Urdu (Table 2). A summary of identified screening tools is available (Additional file 4). Table 2Screening toolsAuthor (year)CountryScreening tool(s)Language(s)No. of questionsType of violenceScreening approachTimepoint for screening (period)SensitivitySpecificityAlmqvist [28]SECTS-B; ViFSwedishCTS-B: 10, ViF: 4PHY/EMO/SEXFace-to-facePostpartum (< 1 year)xxAndreasen [35]DK, ESWAST; AASDanish, SpanishWAST: 2,AAS: 5PHY/EMO/SEXDigitalPregnancy (mean GA 8.9–17.3)xxAndreasen [43]DK, ESAAS; WAST; ISADanish,SpanishAAS: 5,WAST: 2,ISA: 30PHY/EMO/SEXDigitalPregnancy (10–22 weeks)xxEngström [18]SECAS; PSQCAS: 30,PSQ: 3PHY/EMO/SEXDigital, paperPost partum (0–18 months)47%a91%aEikemo [20]SEAASSwedishAAS: 6PHY/EMO/SEXFace-to-facePregnancy (mean GA 22)xxEikemo [19]SEAASSwedishN/APHY/EMO/SEXFace-to-facePregnancy (mean GA 25)xxEscribà-Agüir [21]ESAAS; ISASpanishAAS: 5,ISA: 30PHY/EMO/SEXFace-to-facePregnancy (N/A)6.9–100%b> 97%bFernández-López [9]DK, ESWAST-SF; AASDanish, SpanishWAST-S: 2, AAS: 5PHY/EMO/SEXDigital, face-to-facePregnancy (N/A)xxFinnbogadóttir [33]SENorAQ; AASSwedish, EnglishNorAQ: 13,AAS: 1PHY/EMO/SEXSelf-reportPregnancy (GA 13)xxFinnbogadóttir [22]SENorAQ; AASSwedish, EnglishNorAQ: 13,AAS: 1PHY/EMO/SEXSelf-reportPregnancy (GA 13)xxFlaathen [41]NOCASR-SF; AASNorwegian, English, Urdu, SomaliCASR-SF: 15,AAS: 5PHY/EMO/SEXDigitalPregnancy (any GA) and postpartum (3 months)xxFlaathen [21]NOCASR-SF; AASNorwegian, English, Urdu, SomaliCASR-SF: 15,AAS: 5PHY/EMO/SEXDigitalPregnancy (any GA)xxHadjigeorgiou [29]CYKINDEXGreek, English30Conflicts/PHYFace-to-facePregnancy (any GA)xxLukasse [7]BE, IS, DK, EE, NO, SENorAQFlemish, Icelandic, Danish, Estonian, Russian, Norwegian, SwedishNorAQ: 13PHY/EMO/SEXFace-to-face, digitalPregnancy (approx. GA 20)xxMartin-de-las-Heras [42]ESISASpanishISA: 30PHY/EMO/SEX/Face-to-facePostpartumxxMcConnell [30]GBPARTNR;ABIEnglishPARTNR: 5,ABI: 58Controlling behaviourFace-to-faceDuring pregnancy and postpartum (< 5 years)xxÖzkan-Şat [24]TRHITSTurkishHITS: 4PHY/EMOFace-to-facePost partum (48th hours following birth)xxStöckl [31]DEAASGermanN/APHY/EMO/SEXSelf-report, face-to-facePostpartum (1–7 days after)xxSvavarsdottir [25]ISWASTIcelandic, EnglishWAST: 8PHY/EMO/SEXSelf-report, face-to-facePregnancy (first trimester)xxSørbø [34]NONorAQ; AASNorAQ: 2,AAS: 1PHY/EMO/SEXPostal mailPregnancy (GA 18, GA 30), postpartum (6 months)xxVelasco [26]ESAAS; ISASpanishAAS: 4,ISA: 30PHY/EMO/SEXFace-to-facePostpartumxxVivilaki [27]GRWASTGreekWAST: 8PHY/EMO/SEXFace-to-facePostpartum (avg. 2 days ostpartum)xxVivilaki [44]GRWAST; PVSGreekWAST: 8,PVS: 3PHY/EMO/SEXFace-to-facePostpartum99.7%c64.4%cZapata-Calvente [40]ESAAS; WAST-SFSpanishWAST-SF: 2,AAS: 5PHY/EMOFace-to-facePregnancy (first and third trimester)91.4%d76%daResults of PSQbResults of ASS: 33.3% (severe physical), 22.9% (nonsevere psychological), 6.9% (nonsevere physical), 100% (severe psychological)cResults of WAST with a cut-off score of 1: 99.7% for emotional and physical abuse, 64.4% for emotional and physical abusedResults of WAST-SFAbbreveations: Conflict Tactics Scale-Brief (CTS-B); Violence in the Family (ViF); Women Abuse Screening Tool (WAST); Abuse Assessment Screen (AAS); Index of Spouse Abuse (ISA); Composite Abuse Scale (CAS); Parent Screening Questionnaire (PSQ); Women Abuse Screening Tool-Short (WAST-Short); NorVold Abuse Questionnaire (NorAQ); Composite Abuse Scale Short Form-Revised (CASR-SF); KINDEX Mum Screen; Partner Abuse Risk, Treatment Need and Responsivity (PARTNR); Abusive Behavior Inventory (ABI); Hurt, Insulted, Threatened with Harm, and Screamed (HITS); Partner Violence Screen (PVS) Screening tools WAST: 2, AAS: 5 Danish, Spanish AAS: 5, WAST: 2, ISA: 30 CAS: 30, PSQ: 3 AAS: 5, ISA: 30 NorAQ: 13, AAS: 1 NorAQ: 13, AAS: 1 CASR-SF: 15, AAS: 5 CASR-SF: 15, AAS: 5 PARTNR; ABI PARTNR: 5, ABI: 58 NorAQ: 2, AAS: 1 AAS: 4, ISA: 30 WAST: 8, PVS: 3 WAST-SF: 2, AAS: 5 aResults of PSQ bResults of ASS: 33.3% (severe physical), 22.9% (nonsevere psychological), 6.9% (nonsevere physical), 100% (severe psychological) cResults of WAST with a cut-off score of 1: 99.7% for emotional and physical abuse, 64.4% for emotional and physical abuse dResults of WAST-SF Abbreveations: Conflict Tactics Scale-Brief (CTS-B); Violence in the Family (ViF); Women Abuse Screening Tool (WAST); Abuse Assessment Screen (AAS); Index of Spouse Abuse (ISA); Composite Abuse Scale (CAS); Parent Screening Questionnaire (PSQ); Women Abuse Screening Tool-Short (WAST-Short); NorVold Abuse Questionnaire (NorAQ); Composite Abuse Scale Short Form-Revised (CASR-SF); KINDEX Mum Screen; Partner Abuse Risk, Treatment Need and Responsivity (PARTNR); Abusive Behavior Inventory (ABI); Hurt, Insulted, Threatened with Harm, and Screamed (HITS); Partner Violence Screen (PVS) Reported sensitivity varied widely (6.9–100%), depending on the screening tool and the type and severity of IPV assessed. Sensitivity was generally lower for minor physical or psychological violence and higher for severe or combined abuse. Specificity was more consistently high ranging from 64.4% to more than 97%. The WAST-SF demonstrated high sensitivity (> 90%) with moderate-to-high specificity, whereas the CAS and PSQ showed moderate sensitivity and high specificity. IPV screening was primarily conducted through a face-to-face approach carried out by trained healthcare professionals (usually midwives), who directly administered self-report questionnaires to participants (n = 16). Digital screening approaches, whereby participants completed self-report questionnaires via web-based platforms was less frequently used (n = 5). Mixed screening methods were also adopted, using both digital and face-to-face approach (n = 2). Finally, an exclusively postal mail–based approach was used in certain instances (n = 1). In 13 studies, women were mostly screened once during pregnancy; in eight, once postpartum; and only three included screening in both periods. Healthcare-based screening programmes Eight countries recommended specific screening tools, which were primarily AAS and WAST, similarly to the findings of the literature search. In most countries specific screening tools were not reported. Timing of screening was recommended both in pregnancy and postpartum in most countries (n = 10) and only in pregnancy in seven countries. Screening was primarily done by midwives in person (n = 9), whereas some countries recommended both in person and questionnaire screening (n = 6). Twelve countries detected specific types of violence in their screening programmes. Eight of them screened specifically for physical and psychological violence, while three countries screened for physical, psychological and sexual violence (Fig. 2). Universal screening approach was reported in 13 countries (59,1%) and risk- based screening approach was reported in four countries (18,2%) whilst it was not possible to determinie the screening approach in the data delivered by the remaining five countries (Additional file 3). Heatmap over scientific and healthcare-based screening programmes Quality assessment Assessment of the cross-sectional studies identified three main concerns. Notably, 9 out of 13 did not justify sample size, limiting evaluation of statistical power and potentially affecting the reliability of their findings [7, 9, 18–20, 23, 25, 27, 44]. None of the studies reported specific strategies to address or categorise non-responders, increasing the risk of selection bias. Information on non-responders was often incomplete or absent, limiting generalisability. In mixed-method studies, insufficient justification of the design and inadequate handling of divergences between quantitative and qualitative data reduced interpretability of the integrated findings [28–31]. However, the only RCT study [41], demonstrated low risk of bias in all domains, indicating a high level of methodological rigour. Among intervention cohort studies, Andreasen et al. [35] was judged at serious risk of bias, while Andreasen et al. [43] showed a low risk of bias. Additionally, both studies were affected by uncontrolled confounding factors and by missing outcome data. Regarding exposure cohort studies assessed with ROBINS-E, Finnbogadóttir et al. [33] and Sorbo et al. [34] showed some concerns related to uncontrolled confounding factors. However, Sorbo et al. [34] demonstrated a reduced risk of bias, suggesting reliable results, though interpreted with caution. Conversely, the study by Martin-de-las-Heras and colleagues (2019) was classified as a very high risk of bias in the preliminary assessment, precluding further evaluation. However, its findings should be interpreted with extreme caution. Lastly, in one study [40] applicability issues were generally low across all domains. However, the domain “index test” was shown to have a significant risk of bias, indicating caution when evaluating sensitivity and specificity because of potential bias. Detailed quality assessments for all included studies are provided (Additional file 5). Discussion This review highlights considerable heterogeneity in IPV screening practices during the antenatal and post partum period across Europe, including variation in types af IPV assessed, screening tools used and timing and approaches to screening. The absence of a universally accepted standard screening tool may reflect broader uncertainty regarding optimal strategies for IPV identification within the maternal healthcare setting. Among scientific studies, the most commonly used IPV screening tools were the Abuse Assessment Screen (AAS) and the Women Abuse Screening Tool (WAST). This finding is consistent with findings from previous reviews, which also identified AAS and WAST among the most commonly used IPV screening tools [47, 48]. This continued use of a limited number of established tools may reflect not only their acceptable psychometric properties, but also their feasibility, brevity and ease of implementation in routine antenatal and postpartum care, where practical constraints often influence screening tool selection. Beyond patterns of tool use, the diagnostic performance of screening tools further informs interpretation of IPV identification practices. In this review, few studies reported diagnostic accuracy, showing wide variation in sensitivity but generally high specificity. Lower sensitivity was found for less severe physical and psychological IPV, suggesting that some tools may miss significant abuse in the perinatal period. Overall, no single tool appears to optimise both sensitivity and specificity, and the appropriate balance may depend on the intended screening approach. For example, higher sensitivity could be considered in risk-based screening to reduce missed cases, whereas higher specificity might be preferable in universal screening to avoid unnecessary follow-up. Most screening approaches relied on face-to-face administration by healthcare providers, primarily midwives. Digital screening approaches were less commonly used, despite their potential to facilitate disclosure [49, 50]. Lastly, the timing and screening approach varied across European countries, reflecting the lack of an integrated approach to perinatal IPV screening. This finding is consistent with previous evidence highlighting suboptimal and inconsistent implementation of IPV screening in clinical practice [51]. Furthermore, in line with previous research [12, 49], the majority of the included studies in our scoping review examined physical, psychological/emotional, and sexual violence. Less overt forms of abuse, such as coercive control, economic abuse, and digital abuse, have recieced less attention. The limited focus on economic and digital abuse may reflect the historical emphasis on more visible forms of IPV, as well as the predominant use of AAS and WAST, which do not capture these forms of violence. Additionally, as noted in prior research [12, 49], there is a considerable variation in screening approaches, and timing of screening, demonstrating the difficulty of achieving standardisation in the practice. In contrast to global reviews, this scoping review provides a Europe-focused perspective, including both peer-reviewed and grey literature, thereby reflecting the current European landscape of real-world implementation and guidelines not captured in scientific publications. Strengths and limitations To the best of our knowledge, this is the first comprehensive mapping of IPV screening tools and practices within European healthcare systems. It offers a foundation for future research, supports efforts to harmonise screening approaches, and may inform clinical and policy decisions regarding implementation, effectiveness, and transferability across comparable European contexts. This review is strengthened by its combination of insights from the literature with practical experience from European countries, including those countries that have not necessarily conducted research in this area. Despite this, several limitations should be considered regarding the study results. Although a comprehensive search strategy was used, relevant studies may have been missed, particularly grey literature and unpublished guidelines. Some studies may have been excluded due to the 15-year time frame and language restriction. However, the time limit reduced heterogeneity from outdated frameworks, and inclusion of English-language publications ensured consistent assessment. The mapping also showed that several countries with national programmes were not represented in the peer-reviewed literature. While this does not imply lower quality of these healthcare-based screening programmes, it may limit the ability to assess their implementation and contextual effectiveness across settings. Further, despite the inclusion of studies from multiple European countries, the evidence base is still concentrated in a limited number of settings, particularly in Scandinavian, impeding the generalisability of the findings across European healthcare settings. Data were collected across multiple levels for the mapping of healthcare-based programmes; however, no information was obtained from several countries, particularly in Southern and Eastern Europe. This does not imply absence of such programmes. Although consultations were conducted with relevant professionals and health authorities, it cannot be confirmed that leading experts in the field were included. The overall methodological quality of the studies varied across study designs. Common limitations include sample size justification, poor handling of non-responders, and uncontrolled confounding factors. Hence, the interpretation of the results should be taken with caution due to different values for detecting violence within screening tools. Lastly, the lack of focus on ethnic minorities and socially disadvantaged populations limits the generalisability of the results and raises concerns about equity in IPV screening. Practice and policy implications The findings of the current study should be interpreted in the light of the ongoing debate regarding IPV screening strategies in the antenatal and postpartum period [49]. First, the findings of this review suggest that screening is often conducted at a single time point, despite IPV being a dynamic phenomenon that can emerge or escalate during the pregnancy and the postpartum period. Future studies could focus more on the timing and frequency of screening, evaluating the utility and effectiveness of providing repeated assessments throughout the perinatal period. Second, while WHO guidelines [11] recommend universal screening, others suggest a more cautious approach or risk-based approach. Universal screening was not always explicitly stated; however, most studies assessed all eligible antenatal and postpartum participants, indicating its application in heterogeneous populations. Similarly, among countries with national recommendations identified through contact with EU countries, most recommended universal rather than risk-based screening approaches. However, the presence of national recommandations does not nescessarily reflect the extent to which these screening approaches are implemented in clinical practice. WHO guidelines further emphasise that screening should be integrated into systems ensuring appropriate follow-up, intervention, and support during the perinatal period [11]. Third, screening was primarily conducted face-to-face; however, digital systems have been proposed in some countries and warrant further exploration, as they may facilitate earlier identification, access to care, and disclosure of IPV [43]. Finally, screening tools concerning coercive control, economic abuse, and digital abuse should be considered in the scientific debate in order to incorporate the less overt forms of abuse into IPV screening tools. Conclusion This scoping review synthesizes scientific literature and healthcare-based programmes addressing IPV screening in the antenatal and postpartum period. Results suggest that firm conclusions cannot be drawn due to substantial heterogeneity in screening tools, timing, and practices. Evidence within the European context remains limited. The Abuse Assessment Screen (AAS) and the Woman Abuse Screening Tool (WAST) were most frequently reported, yet data on their clinical performance, particularly regarding sensitivity and specificity, are scarce. Physical, emotional and sexual violence are the types most often screened for. In contrast different forms of violence including digital and economic violence are not included in most screening tools. Overall, the balance between sensitivity and specificity appears context-dependent and related to whether screening is risk-based or universal. Greater comparability and integration of tools and programmes are needed to support early identification of IPV and protect maternal and child health during this vulnerable period. Among the countries that recommended screening in relation to maternity care, most recommended an universal screening approach. Future studies could develop comparative studies enabling comparisons between tools within a country, as well as practices across countries. Supplementary Information Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Supplementary Material 5. Acknowledgements We thank Andreas Lundh from Centre for Evidence-Based Medicine Odense (CEBMO) and Cochrane Denmark (University of Southern Denmark) for providing feedback on the review. Further we thank, research librarian Mette Brandt, for assistance in the literature search. Authors’ contributions AKN made the protocol with contributions from authors MPN, ALB, VD, SG, KA, LDP, PM, JS and DSL. AKN and MNP screened for eligible articles and did the data extraction. Disagreement was solved through discussion. ALB and SG contacted health authorities within Europe. AKN, MPN and ALB designed the tables and figures with input from DSL. AKN and MNP wrote the first draft of the article, which was reviewed by all co-authors. Funding Open access funding provided by University of Southern Denmark. This work was supported by the European Union CERV (CERV-2024-DAPHNE) Program under Grant Agreement [No. 101195161]. Data availability All data generated or analysed during this study are included in this published article and its supplementary information files. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Supplementary Material 5. Data Availability Statement All data generated or analysed during this study are included in this published article and its supplementary information files.